The teams of the academic departments of addiction medicine in Lyon work closely with the CRNL PSYR2 team on the neuroscience of addictions.
Guillaume Sescousse, Research Fellow at INSERM in the PSYR2 team, also works with the SUAL to develop neuroscience research projects.
More information about the PSYR2 team here
CERMEP is an in vivo preclinical and clinical imaging platform that is open to practitioners and researchers from the academic and industrial spheres.
The teams of the academic departments of addiction medicine in Lyon and the PSYR2 research team collaborate closely with CERMEP on neuroimaging studies on addictions, and in particular on the ongoing CANDI (cannabis and thought disorder in schizophrenia) study.
More information on CERMEP here
SESSTIM is a joint INSERM and Aix-Marseille University research centre. It brings together interdisciplinary teams in economic and social sciences, social epidemiology, biostatistics and medical informatics.
The teams of the academic departments of addiction medicine in Lyon work more specifically with the QuanTIM team (Director: Roch Giorgi) and with Patrizia Carrieri (epidemiologist).
The collaboration between the SUAL and SESSTIM currently focuses on the FANTASIO study : Factors of access to new therapies with antiviral drugs for subjects infected with hepatitis C and receiving opioid agonist treatments: a quasi-exhaustive analysis based on the French insurance claims database (SNIIRAM).
SESSTIM is also involved in the upcoming CARAMEL project: Cannabidiol for reducing alcohol drinking in AUD and modifying the effects of alcohol on the liver and the brain (PHRC-N 2018; expected beginning in 2020).